Gliolan

DRUG5 trials

Sponsors

Abramson Cancer Center at Penn Medicine, medac GmbH, University Hospital, Lille, Universität Münster

Conditions

Anal DysplasiaBrain NeoplasmCarcinoma in SituGlioblastoma

Phase 1

PDT Plus Vitamin D3 for Anal Dysplasia

WithdrawnNCT02698293

Abramson Cancer Center at Penn MedicineAnal Dysplasia, Carcinoma in Situ

Start: 2019-12-01End: 2022-08-03Updated: 2026-08-04

Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas

CompletedNCT02755142

medac GmbHBrain Neoplasm

Start: 2000-02-29End: 2001-06-30Updated: 2016-05-23

Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor

RecruitingNCT05590689

Universität MünsterGlioblastoma

Start: 2022-11-09End: 2028-01-01Target: 34Updated: 2026-06-23

Phase 2

Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma

CompletedNCT04391062

University Hospital, LilleGlioblastoma

Start: 2021-09-28End: 2024-03-25Updated: 2025-12-05

Unknown Phase

INtraoperative photoDYnamic Therapy of GliOblastoma

CompletedNCT03048240

University Hospital, LilleGlioblastoma

Start: 2017-05-05End: 2021-04-28Updated: 2026-02-05

Related Papers

Long term follow-up of patients with newly diagnosed glioblastoma treated by intraoperative photodynamic therapy: an update from the INDYGO trial (NCT03048240)

Journal of Neuro-Oncology2024-05-1619 citations

ALA-RDT in GBM: protocol of the phase I/II dose escalation trial of radiodynamic therapy with 5-Aminolevulinic acid in patients with recurrent glioblastoma

Radiation Oncology2024-01-2217 citations

Standardized intraoperative 5-ALA photodynamic therapy for newly diagnosed glioblastoma patients: a preliminary analysis of the INDYGO clinical trial.

2021-03-2070 citations

Tribulations in medicine: designing and implementing a trial of PDT plus vitamin D3 for high-grade anal dysplasia and microinvasive anal cancer (Conference Presentation)

2020-03-10